APP
VIR icon

Avantax Planning Partners’s Vir Biotechnology VIR Stock Holding History

Avantax Planning Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,486
Closed -$371K – 456
2024
Q4 		$371K Sell
50,486
-873
-2% -$6.89K 0.01% 297
2024
Q3 		$385K Hold
51,359
– – 0.01% 297
2024
Q2 		$457K Hold
51,359
– – 0.01% 298
2024
Q1 		$520K Buy
+51,359
New +$523K 0.02% 289

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Avantax Planning Partners's VIR Position: Q1 2025 in Review

Avantax Planning Partners sold out of Vir Biotechnology (VIR) in Q1 2025, closing a stake of 50,486 shares — an estimated $371K sold.

Avantax Planning Partners first reported a position in VIR in Q1 2024 and held it in 4 quarters. The position peaked at $520K in Q1 2024. 233 funds tracked by Wall St. Rank hold VIR as of Q1 2025.

  • Avantax Planning Partners reported no remaining Vir Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Avantax Planning Partners sold 50,486 Vir Biotechnology shares in Q1 2025, an estimated $371K.
  • Avantax Planning Partners first reported a position in Vir Biotechnology in Q1 2024 and held it in 4 quarters.
  • Avantax Planning Partners's Vir Biotechnology position peaked at $520K in Q1 2024.
  • 233 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2025.

Based on Avantax Planning Partners's 13F filing for Q1 2025, filed 29 Apr 2025.